Quellen- und Literaturangaben

Referenzen

1. Ferlay J, Bray P, Pizani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, Version 2 0 IARCPress, Lyon, 2004. 
Siehe: http://www.iarc.fr  
Letzter Zugriff: 20. September 2005.

2. Basen-Engquist K, Paskett ED et al.. Cervical cancer. Cancer 2003; 98: 2009-2014.

3. Wenzel L, DeAlba I et al.. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 2005; 97: 310-317.

4. Pearman T. Quality of life and psychosocial adjustment in gynecologic cancer survivors. Health Qual Life Outcomes 2003; 1: 33.

5. Bell S, Porter M et al.. Psychological response to cervical screening. Prev Med 1995; 24: 610-616.

6. Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998; 34: 1889-1893.

7. Jacob M, Broekhuizen FF et al.. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet 2005; 89 Suppl 2: S13-S20.

8. Sankaranarayanan R, Budukh AM et al.. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001; 79: 954-962.

9. Sankaranarayanan R, Gaffikin L et al.. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89 Suppl 2: 4-12.

10. Greimel E, Thiel I et al.. Prospective assessment of quality of life of female cancer patients. Gynecol Oncol 2 002; 85: 140-147.

11. Bosch FX, Lorincz A, et al.. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65.

12. Walboomers JM, Jacobs MV et al.. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19.

13. Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19.

14. de Villiers EM,  Heterogeneity of the Human Papillomavirus Group J Virology 1989; 63: 4898-903.

15. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 Suppl 1: 16-24.

16. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 3-13.

17. Brown DR, Shew ML et al.. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191: 182-192.

18. Ho GY, Bierman R et al.. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.

19. Clifford GM, Gallus S et al.. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-998.

20. Muñoz N, Bosch FX et al.. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.

21. Muñoz N, Bosch FX et al.. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.

22. Bjorge T, Dillner J et al.. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997; 315: 646-649.

23. Chen R, Aaltonen LM et al.. Human papillomavirus type 16 in head and neck carcinogenesis. Rev Med Virol 2005.

24. Frisch M, Glimelius B et al.. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337: 1350-1358.

25. Pow-Sang MR, Benavente V et al.. Cancer of the penis. Cancer Control 2002; 9: 305-314.

26. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16: 1-17.

27. Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 354-359.

28. Prendiville W, Davies P. The Human Papillomavirus. In: Prendiville W, Davis P, eds. The Health Professionals HPV Handbook: Human papillomavirus and cervical cancer. Oxford: Taylor and Francis, 2004b: 11-26.

29. de Villiers EM, Fauquet C, et al.. Classification of papillomaviruses. Virology 2004; 324: 17-27.

30. Franceschi S.  The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 2005; 166: 277-297.

31. Conway K.  Attitudes to Papanicolaou smears. J Psychosom Obstet Gynecol 1996; 17: 189-194.

32. de Jong A, van Poelgeest MI et al.. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-5455.

33. Stanley M.  Immune responses to human papillomavirus. Vaccine 2005.

34. Mayrand MH, Coutlee F et al.. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000; 38: 3388-3393.

35. McIntosh N.  Human papillomavirus and cervical cancer.
 Siehe: http://www.jhpiego.org/scripts/pubs/category_detail.asp?category_id=4.
 Letzter Zugriff: 20. September 2005

36. Franco EL, Duarte-Franco E, et al.. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164: 1017-1025.

37. Gustafsson L, Ponten J et al.. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755-763.

38. Sawaya GF, McConnell KJ et al.. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349: 1501-1509.

39. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343-347.

40. Stuart GC, McGregor SE et al.. Review of the screening history of Alberta women with invasive cervical cancer. CMAJ 1997; 157: 513-519.

41. Harper DM, Franco EL et all. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.

42. van der Graaf Y, Vooijs GP et al. Screening errors in cervical cytologic screening. Acta Cytol 1987; 31: 434-438.

43. Quinn M, Babb P et all. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 904-908.

44. van Leeuwen AW, de Nooijer P et al.. Screening for cervical carcinoma. Cancer 2005; 105: 270-276. SGOC. Programmatic Guidelines for Screening for Cancer of the Cervix in Canada. 1998; 1-36.

45. Vizcaino AP, Moreno V et al.. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75: 536-545.

46. Vizcaino AP, Moreno Vet al.. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000; 86: 429-435.

47. Krebsforschung Großbritannien. Gebärmutterhalskrebs-Inzidenzstatistik für Großbritannien.
 Siehe:  http://info.cancerresearchuk.org/cancerstats/types/cervix/incidence/.
 Letzter Zugriff: 03. Januar 2006

48. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.

49. McCaffery K, Waller J et al.. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 2004; 111: 1437-1443.